Screening compound: InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2

Screening compound: InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2
Screening compound: InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2 alternative view

Chemical Structure Depiction of ChemDiv screening compound
InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

M019-1647

Molecular Formula

C16H15N5O (C16 H15 N5 O)

Compound Name

4-[5-(pyridin-3-yl)-1,2,4-oxadiazol-3-yl]-2-(pyrrolidin-1-yl)pyridine

IUPAC name

4-[5-(pyridin-3-yl)-124-oxadiazol-3-yl]-2-(pyrrolidin-1-yl)pyridine

SMILES

C(CC1)CN1c1nccc(-c2noc(-c3cnccc3)n2)c1

InChI

InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2

InChI Key

OLVAEHSFOXNMRS-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27492652

InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

CNS Targets (44014 compounds)

Fragments Library (11262 compounds)

GPCR Targeted Library (31838 compounds)

SmartTM Library (51161 compounds)

Targeted Diversity Library (40567 compounds)

Akt-Targeted Library (14764 compounds)

Ion Channels Focused Library (26372 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Nervous system
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Skin
  • Nervous system
  • Cardiovascular
Structure:
  • Fragments
Targets:
  • GPCR
  • Kinases
  • Ion Channels
Mechanism of action:
  • Receptor's ligands

References: we are preparing a list of scientific research reports with InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2?
Check Price and Availability of InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of InChI=1S/C16H15N5O/c1-2-9-21(8-1)14-10-12(5-7-18-14)15-19-16(22-20-15)13-4-3-6-17-11-13/h3-7,10-11H,1-2,8-9H2 available by request